SCHEMBL19836464

SCHEMBL19836464

Cc1nc2ccc(B3OC(C)(C)C(C)(C)O3)cc2n1C(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 1/20 0.44
IDO1 P14902 1/20 0.39
TDO2 P48775 1/20 0.39
LPL P06858 5/20 0.37
LIPG Q9Y5X9 5/20 0.37
SNCA P37840 1/20 0.36
CDK1 P06493 2/20 0.36
CDK4 P11802 2/20 0.36
CCNB1 P14635 2/20 0.36
CCND1 P24385 2/20 0.36
CSNK1E P49674 1/20 0.36
CLK1 P49759 1/20 0.36
CLK2 P49760 1/20 0.36
CLK3 P49761 1/20 0.36
GSK3B P49841 1/20 0.36
CDK5 Q00535 1/20 0.36
DYRK1A Q13627 1/20 0.36
CDK5R1 Q15078 1/20 0.36
DYRK2 Q92630 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29827536 1.00 IRAK4 (0.44) IRAK4IDO1TDO2LPLLIPG
SCHEMBL20987137 0.91 IRAK4 (0.39) IRAK4IDO1TDO2LPLLIPG
SCHEMBL19836331 0.83 SNCA (0.41) IRAK4IDO1TDO2LPLLIPG
SCHEMBL29612564 0.83 SNCA (0.41) IRAK4IDO1TDO2LPLLIPG
SCHEMBL6919556 0.82 IRAK4 (0.46) IRAK4IDO1TDO2LPLLIPG
SCHEMBL22272299 0.78 IRAK4 (0.36) IRAK4LPLLIPG
SCHEMBL20045112 0.77 LPL (0.41) IRAK4LPLLIPGESR2PRMT5
SCHEMBL29403292 0.76 CDK4 (0.36) IRAK4LPLLIPGCDK1CDK4
SCHEMBL2511865 0.76 CDK4 (0.36) IRAK4LPLLIPGCDK1CDK4
SCHEMBL18202681 0.76 CSNK1E (0.32) CDK4CCND1CSNK1ECLK1CLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024044757-A1 AMINOPYRIMIDINE AND AMINOTRIAZINE DERIVATIVES AS MYC PROTEIN MODULATORS Sanford Burnham Prebys Medical Discovery Institute (US) 2024-02-29 WO disclosed
CN-114874189-B Substituted heteroaryl derivatives, compositions and uses thereof 深圳市塔吉瑞生物医药有限公司 2023-09-29 CN disclosed
EP-3492462-B1 AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY SHENZHEN TARGETRX INC (CN) 2023-08-30 EP disclosed
EP-3492462-B1 AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY SHENZHEN TARGETRX INC (CN) 2023-08-30 EP disclosed
CN-111377907-B Polysubstituted phenylamino pyrimidine derivative and preparation method and application thereof 杭州百新生物医药科技有限公司 2023-03-28 CN disclosed
CN-113382991-B Aminopyrimidines useful for inhibiting protein tyrosine kinase activity 深圳市塔吉瑞生物医药有限公司 2022-12-27 CN disclosed
CN-114874189-A Substituted heteroaryl derivatives, compositions and uses thereof 深圳市塔吉瑞生物医药有限公司 2022-08-09 CN disclosed
CN-113382991-A Aminopyrimidines useful for inhibiting protein tyrosine kinase activity 深圳市塔吉瑞生物医药有限公司 2021-09-10 CN disclosed
US-11111233-B2 Amino pyrimidine compound for inhibiting protein tyrosine kinase activity SHENZHEN TARGETRX, INC. (CN) 2021-09-07 US disclosed
CN-110818690-B Aminopyrimidines useful for inhibiting protein tyrosine kinase activity 深圳市塔吉瑞生物医药有限公司 2021-08-10 CN disclosed
CN-111377907-A Polysubstituted phenylamino pyrimidine derivative and preparation method and application thereof 杭州百新生物医药科技有限公司 2020-07-07 CN disclosed
WO-2020135507-A1 POLYSUBSTITUTED ANILINOPYRIMIDINE DERIVATIVE AND PREPARATION METHOD AND APPLICATION THEREOF 杭州百新生物医药科技有限公司 2020-07-02 WO disclosed
WO-2020135507-A1 POLYSUBSTITUTED ANILINOPYRIMIDINE DERIVATIVE AND PREPARATION METHOD AND APPLICATION THEREOF 杭州百新生物医药科技有限公司 2020-07-02 WO disclosed
CN-110818690-A Aminopyrimidines useful for inhibiting protein tyrosine kinase activity 深圳市塔吉瑞生物医药有限公司 2020-02-21 CN disclosed
CN-108602802-B Aminopyrimidines useful for inhibiting protein tyrosine kinase activity 深圳市塔吉瑞生物医药有限公司 2020-01-21 CN disclosed
EP-3492462-A1 AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY Shenzhen Targetrx, Inc. (CN) 2019-06-05 EP disclosed
EP-3492462-A1 AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY Shenzhen Targetrx, Inc. (CN) 2019-06-05 EP disclosed
US-20190152954-A1 AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY SHENZHEN TARGETRX, INC. (CN) 2019-05-23 US disclosed
CN-105153119-B Pyridine pyrimidinamine compound or pyridine pyridyl amine compound and its application 广州必贝特医药技术有限公司 2019-01-01 CN disclosed
WO-2018019204-A1 AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY 深圳市塔吉瑞生物医药有限公司 2018-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190152954-A1 AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY LCK, WEE1, JAK1 IRAK4 1234/4885IDO1 451/4885TDO2 437/4885
US-11111233-B2 Amino pyrimidine compound for inhibiting protein tyrosine kinase activity LCK, WEE1, JAK1 IRAK4 1234/4885IDO1 451/4885TDO2 437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.